The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Michael SchieberDepartment of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

Shuo MaDepartment of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USACorrespondence[email protected]

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Fedor Romanov-Michailidis, Chien-Chi Hsiao, Lorenz M. Urner, Soufyan Jerhaoui, Michel Surkyn, Bradley Miller, Ann Vos, Maria Dominguez Blanco, Ruud Bueters, Petra Vinken, Mariette Bekkers, David Walker, Beth Pietrak, Werner Eyckmans, José Luís Dores-Sousa, Seong Joo Koo, William Lento, Marcus Bauser, Ulrike Philippar & Frederik J. R. Rombouts. (2023) Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies. Journal of Medicinal Chemistry 66:9, pages 6122-6148.
Crossref

Toby A. Eyre, Satoshi Hori & Talha Munir. (2021) Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology 40:2, pages 129-159.
Crossref

Xi Yang, Chen Mei, Xiaoying He, Lingjuan He, Xiaoyang Lu, Hongyan Tong & Yan Lou. (2022) Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method. Molecules 27:5, pages 1607.
Crossref

Hind A. Alkhatabi, Samir F. Zohny, Mohammed Razeeth Shait Mohammed, Hani Choudhry, Mohd Rehan, Aamir Ahmad, Farid Ahmed & Mohammad Imran Khan. (2022) Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival. Antioxidants 11:3, pages 461.
Crossref

Xiaofeng Dai, Danjun Wang & Jianying Zhang. (2021) Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis 26:7-8, pages 385-414.
Crossref

Peng-Ju Zhu, Ze-Zhou Yu, Qi-Dong You & Zheng-Yu Jiang. (2020) Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy. Drug Discovery Today 25:10, pages 1873-1882.
Crossref

Rachael Arthur, Beatriz Beatriz Valle-Argos, Andrew J. Steele & Graham Packham. (2020) Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors. Exploration of Targeted Anti-tumor Therapy 1:3, pages 131-152.
Crossref

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date